Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121526 | 0.87 | HDAC1 (0.48) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7128217 | 0.87 | FAAH (0.42) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7122085 | 0.86 | HDAC1 (0.47) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7118281 | 0.86 | ACKR3 (0.40) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7125142 | 0.86 | ACKR3 (0.47) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7161105 | 0.86 | FAAH (0.43) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7117709 | 0.85 | ACKR3 (0.40) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7120510 | 0.85 | HDAC1 (0.50) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7116085 | 0.84 | TUBB4A (0.49) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 | |
| SCHEMBL7224496 | 0.84 | FAAH (0.46) | ACKR3CHRNB2CHRNA7CHRNA4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | ACKR3 1448/4885CHRNB2 557/4885CHRNA7 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.